Management of Acute Variceal Hemorrhage in Decompensated Cirrhosis

Immediate Pre‑Endoscopic Management

• Start a bundled protocol (IV ceftriaxone 1 g daily, octreotide or somatostatin infusion, restrictive transfusion targeting hemoglobin 7–8 g/dL, and arrange endoscopy within 12 h) in critically ill cirrhotic patients with suspected variceal bleed; this reduces mortality, bacterial infection, and re‑bleeding. 1
• Give IV ceftriaxone 1 g immediately on suspicion of gastrointestinal bleeding in any cirrhotic patient, without waiting for endoscopic confirmation. 2
• Limit prophylactic ceftriaxone to a maximum of 7 days. 1
• Provide antibiotics to all cirrhotic patients with GI bleeding, irrespective of Child‑Pugh class or presence of ascites. 3
• In advanced cirrhosis, ceftriaxone is superior to norfloxacin, lowering proven infections from 26 % to 11 % and spontaneous bacterial peritonitis/bacteremia from 12 % to 2 %. 4
• The same antibiotic regimen lowers mortality (RR 0.79), bacterial infections (RR 0.35), and re‑bleeding (RR 0.53). 5

Vasoactive Drug Therapy

• Begin octreotide or another somatostatin analogue infusion as soon as variceal hemorrhage is suspected. 1
• Continue vasoactive infusion for 3–5 days after definitive diagnosis. 1
• Meta‑analyses show vasoactive drugs reduce splanchnic flow and portal pressure, translating to ~30 fewer deaths per 1 000 patients (RR 0.85). 1
• Vasoactive agents must never be used alone; they require concurrent antibiotics and endoscopic therapy. 2

Resuscitation Strategy

• Adopt a restrictive transfusion target of hemoglobin 7–8 g/dL; avoid transfusing to “normal” levels. 3
• Do not give large-volume crystalloid boluses, as they raise portal pressure and precipitate re‑bleeding. 3
• Maintain hemodynamic stability with cautious, goal‑directed blood‑product administration. 3

Airway Protection

• Consider elective endotracheal intubation before endoscopy in patients with hepatic encephalopathy or massive hematemesis to prevent aspiration. 3

Coagulation Management

• Do not routinely give fresh‑frozen plasma, platelets, or fibrinogen concentrates before endoscopy. 6
• Despite abnormal INR or platelet counts, thrombin generation remains normal in cirrhosis; conventional tests do not predict procedural bleeding. 6
• Large volumes of FFP increase portal pressure and intravascular volume without correcting coagulopathy. 7
• Correct coagulopathy only on a case‑by‑case basis when bleeding is refractory to all other measures. 8

Endoscopic Phase (Within 12 h)

• Perform esophagogastroduodenoscopy within 12 hours after initial resuscitation and hemodynamic stabilization. 1
• Early endoscopy facilitates rapid discussion of early TIPS for refractory bleeding. 6
• Esophageal varices: use endoscopic variceal ligation (EVL) rather than sclerotherapy. 3
• Gastric varices type GOV1: treat with EVL as for esophageal varices. 2
• Fundal varices (GOV2, IGV1): apply tissue‑adhesive (N‑butyl‑cyanoacrylate) obliteration; re‑bleeding rates are lower (23 % vs 47 % with EVL). 2

Post‑Endoscopic Management

• Complete the 7‑day ceftriaxone course after endoscopy. 6
• Continue vasoactive drug infusion to complete a total of 3–5 days. 1
• Administer a proton‑pump inhibitor to all patients with portal‑hypertensive bleeding. 1

Rescue and Definitive Therapies

• Early (pre‑emptive) TIPS within 24–72 h is indicated for high‑risk patients: Child‑Pugh C with score < 14, or Child‑Pugh B with active bleeding at endoscopy. 6
• Early TIPS markedly reduces 2‑year mortality in these groups. 6
• Salvage TIPS with a covered stent should be used for bleeding refractory to combined endoscopic and pharmacologic therapy; it achieves hemostasis in ~80 % of cases. 6
• Balloon tamponade (Blakemore or Linton tube) may be employed as a bridge to TIPS for up to 24 h when bleeding cannot be controlled. 6
• Self‑expandable esophageal stents are an alternative bridge, offering comparable 15‑day survival to balloon tamponade. 6

Common Pitfalls to Avoid

• Delaying antibiotics until endoscopic confirmation increases mortality; start them immediately on suspicion. 2
• Assuming Child‑Pugh A patients do not need prophylactic antibiotics is incorrect; universal coverage is recommended. 4
• Over‑transfusing to achieve normal hemoglobin levels raises portal pressure and re‑bleeding risk. 3
• Routine correction of coagulopathy with FFP or platelets is ineffective and may be harmful. 6
• Using vasoactive drugs without concurrent antibiotics is inadequate; combined therapy is mandatory. 2
• Extending antibiotic prophylaxis beyond 7 days promotes resistance without clinical benefit. 2
• Ignoring local antimicrobial resistance patterns can reduce efficacy; ceftriaxone is preferred where quinolone resistance is prevalent. 6

Bowel‑Movement Management for Hepatic Encephalopathy Prevention in Cirrhotic Patients After Melena

Lactulose Titration and Bowel‑Frequency Target

• In cirrhotic patients whose acute melena has been controlled, lactulose should be titrated to achieve 2–3 soft bowel movements per day as secondary prophylaxis for hepatic encephalopathy (HE) 9.

Clinical Benefits and Evidence

• HE recurrence is markedly reduced: lactulose lowers the 14‑month recurrence rate from ≈47 % to ≈20 % in patients who have recovered from an overt HE episode 9.
• The 2–3 BM/day target is effective regardless of the presence of active melena, because HE prevention remains critical after gastrointestinal bleeding 9.
• Cirrhotic patients are at high risk of HE after GI bleeding due to increased ammonia production from blood in the gut; achieving the bowel‑frequency target decreases intestinal ammonia absorption, limits protein fermentation, and cuts the near‑50 % HE‑recurrence rate seen in untreated patients 9.

Special Considerations

• Although some cirrhotic patients exhibit faster proximal small‑intestinal transit (≈1.27 m/h vs 1.00 m/h in controls), this does not negate the need for lactulose titration to reach the 2–3 BM/day goal for HE prevention 9.
• Protein restriction is not advised in HE; instead, optimizing bowel frequency with lactulose is the preferred strategy 9.

Management Recommendations

• Do not wait for overt HE before initiating lactulose; prophylactic use after gastrointestinal bleeding is recommended 9.
• Rifaximin should not be used as monotherapy; add it only after a second HE episode within 6 months despite adequate lactulose therapy 9.
• Practical algorithm (all steps supported by the same evidence):

Maintaining 2–3 bowel movements per day is a cornerstone of cirrhosis management and should be upheld once the acute melena episode is addressed 9.